Evidence in the treatment of dyslipidemia in the metabolic syndrome

Li Chin Sung, Ji Hung Wang

Research output: Contribution to journalReview article

Abstract

The metabolic syndrome is a cluster of cardiovascular risk factors as characteristic and correlated with cardiovascular disease and the development of the diabetes mellitus. The characters of dyslipidemia are the hypertriglyceridemia, low high-density lipoprotein cholesterol and small dense low-density lipoprotein cholesterol. As to the patient having a cardiovascular disease (such as coronary artery disease, stroke, or peripheral artery occlusion) or the diabetes mellitus, the 2001 National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III suggests reducing the serum low-density lipoprotein cholesterol with statin. However, there remains a relatively high residual risk of morbidity or mortality in patients with the metabolic syndrome or diabetes mellitus, and this is of growing importance because of the increasing prevalence of obesity and its associated comorbidities in the world. The treatment to achieve aggressive goals is of paramount importance. This article reviews pathophysiology and emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome.

Original languageEnglish
Pages (from-to)305-317
Number of pages13
JournalJournal of Internal Medicine of Taiwan
Volume19
Issue number4
Publication statusPublished - Aug 2008
Externally publishedYes

Fingerprint

Dyslipidemias
LDL Cholesterol
Diabetes Mellitus
Cardiovascular Diseases
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypertriglyceridemia
HDL Cholesterol
Comorbidity
Coronary Artery Disease
Therapeutics
Arteries
Obesity
Stroke
Cholesterol
Morbidity
Education
Mortality
Serum

Keywords

  • Dyslipidemia
  • Evidence-based medicine
  • Metabolic Syndrome

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Evidence in the treatment of dyslipidemia in the metabolic syndrome. / Sung, Li Chin; Wang, Ji Hung.

In: Journal of Internal Medicine of Taiwan, Vol. 19, No. 4, 08.2008, p. 305-317.

Research output: Contribution to journalReview article

@article{e484d442af6e4152aaef0dcfaf53f229,
title = "Evidence in the treatment of dyslipidemia in the metabolic syndrome",
abstract = "The metabolic syndrome is a cluster of cardiovascular risk factors as characteristic and correlated with cardiovascular disease and the development of the diabetes mellitus. The characters of dyslipidemia are the hypertriglyceridemia, low high-density lipoprotein cholesterol and small dense low-density lipoprotein cholesterol. As to the patient having a cardiovascular disease (such as coronary artery disease, stroke, or peripheral artery occlusion) or the diabetes mellitus, the 2001 National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III suggests reducing the serum low-density lipoprotein cholesterol with statin. However, there remains a relatively high residual risk of morbidity or mortality in patients with the metabolic syndrome or diabetes mellitus, and this is of growing importance because of the increasing prevalence of obesity and its associated comorbidities in the world. The treatment to achieve aggressive goals is of paramount importance. This article reviews pathophysiology and emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome.",
keywords = "Dyslipidemia, Evidence-based medicine, Metabolic Syndrome",
author = "Sung, {Li Chin} and Wang, {Ji Hung}",
year = "2008",
month = "8",
language = "English",
volume = "19",
pages = "305--317",
journal = "Journal of Internal Medicine of Taiwan",
issn = "1016-7390",
publisher = "臺灣內科醫學會",
number = "4",

}

TY - JOUR

T1 - Evidence in the treatment of dyslipidemia in the metabolic syndrome

AU - Sung, Li Chin

AU - Wang, Ji Hung

PY - 2008/8

Y1 - 2008/8

N2 - The metabolic syndrome is a cluster of cardiovascular risk factors as characteristic and correlated with cardiovascular disease and the development of the diabetes mellitus. The characters of dyslipidemia are the hypertriglyceridemia, low high-density lipoprotein cholesterol and small dense low-density lipoprotein cholesterol. As to the patient having a cardiovascular disease (such as coronary artery disease, stroke, or peripheral artery occlusion) or the diabetes mellitus, the 2001 National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III suggests reducing the serum low-density lipoprotein cholesterol with statin. However, there remains a relatively high residual risk of morbidity or mortality in patients with the metabolic syndrome or diabetes mellitus, and this is of growing importance because of the increasing prevalence of obesity and its associated comorbidities in the world. The treatment to achieve aggressive goals is of paramount importance. This article reviews pathophysiology and emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome.

AB - The metabolic syndrome is a cluster of cardiovascular risk factors as characteristic and correlated with cardiovascular disease and the development of the diabetes mellitus. The characters of dyslipidemia are the hypertriglyceridemia, low high-density lipoprotein cholesterol and small dense low-density lipoprotein cholesterol. As to the patient having a cardiovascular disease (such as coronary artery disease, stroke, or peripheral artery occlusion) or the diabetes mellitus, the 2001 National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III suggests reducing the serum low-density lipoprotein cholesterol with statin. However, there remains a relatively high residual risk of morbidity or mortality in patients with the metabolic syndrome or diabetes mellitus, and this is of growing importance because of the increasing prevalence of obesity and its associated comorbidities in the world. The treatment to achieve aggressive goals is of paramount importance. This article reviews pathophysiology and emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome.

KW - Dyslipidemia

KW - Evidence-based medicine

KW - Metabolic Syndrome

UR - http://www.scopus.com/inward/record.url?scp=52249095497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52249095497&partnerID=8YFLogxK

M3 - Review article

VL - 19

SP - 305

EP - 317

JO - Journal of Internal Medicine of Taiwan

JF - Journal of Internal Medicine of Taiwan

SN - 1016-7390

IS - 4

ER -